

IGI LABORATORIES, INC  
Form 8-K  
December 22, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 22, 2014**

**IGI Laboratories, Inc.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-08568</b>	<b>01-0355758</b>
<b>(State or other jurisdiction</b>	<b>(Commission</b>	<b>(I.R.S. Employer</b>
<b>of incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>

**105 Lincoln Avenue, Buena, New Jersey 08310**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (856) 697-1441**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On December 22, 2014, IGI Laboratories, Inc. (the “Company”) announced the closing of the exercise in full by the initial purchasers of their option to purchase an additional \$18.75 million aggregate principal amount of the Company’s 3.75% Convertible Senior Notes due 2019, in connection with the Company’s previously announced private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. A copy of the Company’s press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
--------------------	--------------------

99.1	Press Release issued by IGI Laboratories, Inc., dated December 22, 2014, announcing the closing of the initial purchasers’ option to purchase additional convertible senior notes due 2019.
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI Laboratories, Inc.**

By: /s/ Jenniffer Collins  
Jenniffer Collins  
Chief Financial Officer

Date: December 22, 2014